Healthcare
Live Price
Offline$19.78
+6.46% today
1Y Change
+96.20%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zenas BioPharma, Inc. (ZBIO) is a Healthcare stock with a market cap of $960.00M and listed on NASDAQ. The stock last traded around $19.78 and up 96.2% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +100.0%, EPS growth of -124.5%, a dividend yield of 0.0%. What stands out right now is revenue +100.0%, EPS -124.5%, free cash flow -43.9% with operating margin -2163.8% and ROIC -67.2%. Valuation already assumes a fairly strong business story at price/sales 96.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ZBIO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZBIO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ZBIO Max Drawdown
-64.79%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ZBIO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
Latest Revenue
—
Latest Net Income
—
Free Cash Flow
—
Revenue Growth
+100.0%
EPS Growth
-124.5%
Gross Margin
-380.4%
Net Margin
-3777.4%
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.